CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Analysts at Oppenheimer Holdings lifted their Q4 2017 EPS estimates for shares of CytomX Therapeutics in a report released on Wednesday. Oppenheimer Holdings analyst L. Cann now expects that the biotechnology company will post earnings per share of ($0.64) for the quarter, up from their prior estimate of ($0.67). Oppenheimer Holdings currently has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for CytomX Therapeutics’ Q1 2018 earnings at ($0.01) EPS, Q2 2018 earnings at ($0.08) EPS, Q3 2018 earnings at ($0.14) EPS, Q4 2018 earnings at ($0.18) EPS, FY2018 earnings at ($0.42) EPS, FY2019 earnings at ($1.78) EPS and FY2021 earnings at ($1.66) EPS.
CTMX has been the subject of several other reports. Wedbush assumed coverage on CytomX Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $26.00 target price for the company. Cann restated a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. BidaskClub cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Jefferies Group LLC set a $25.00 target price on CytomX Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. CytomX Therapeutics currently has a consensus rating of “Hold” and an average price target of $31.88.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/12/oppenheimer-holdings-equities-analysts-raise-earnings-estimates-for-cytomx-therapeutics-inc-ctmx.html.
CytomX Therapeutics (NASDAQ CTMX) opened at $19.75 on Friday. CytomX Therapeutics has a 52-week low of $10.03 and a 52-week high of $24.67.
In other news, major shareholder Robert I. Tepper sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $18.00, for a total value of $360,000.00. Following the completion of the transaction, the insider now directly owns 54,293 shares in the company, valued at approximately $977,274. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Michael Kavanaugh sold 48,368 shares of the company’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $24.34, for a total value of $1,177,277.12. The disclosure for this sale can be found here. Insiders sold a total of 187,355 shares of company stock valued at $4,031,706 over the last quarter. Company insiders own 4.70% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc boosted its holdings in shares of CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 1,434 shares in the last quarter. Macquarie Group Ltd. purchased a new position in shares of CytomX Therapeutics in the 3rd quarter worth about $107,000. First Quadrant L P CA purchased a new position in shares of CytomX Therapeutics in the 2nd quarter worth about $160,000. Cubist Systematic Strategies LLC purchased a new position in shares of CytomX Therapeutics in the 2nd quarter worth about $174,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CytomX Therapeutics in the 1st quarter worth about $190,000. Hedge funds and other institutional investors own 60.02% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.